Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands

被引：225

作者：

Cao, Yihai ^{[1
]}

机构：

[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden

来源：

SCIENCE SIGNALING | 2009年 / 2卷 / 59期

关键词：

ENDOTHELIAL-GROWTH-FACTOR; FACTOR GENE-EXPRESSION; INHIBITS TUMOR-GROWTH; HIGH-AFFINITY BINDING; TYROSINE-KINASE; FACTOR-B; FACTOR RECEPTOR-1; SIGNAL-TRANSDUCTION; FACTOR-I; VASCULAR-PERMEABILITY;

D O I：

10.1126/scisignal.259re1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Vascular endothelial growth factor-A (VEGF-A) is a key target for new antiangiogenic drugs for the treatment of both malignant and nonmalignant human diseases. Vascular effects of VEGF family members are mainly mediated by VEGF receptor 2 (VEGFR2). Conversely, the function and signaling of VEGFR1, which is present on endothelial and nonendothelial cells, are poorly understood. Intriguingly, two of five members in the VEGF family-VEGF-B and placental growth factor (PlGF)-are exclusive ligands for VEGFR1 and do not interact with the other VEGFRs, VEGFR2 and VEGFR3. These VEGFR1-specific ligands may be important therapeutic targets for the treatment of cancer. This Review discusses the distinctive roles of VEGFR1 and its ligands PlGF and VEGF-B in the mediation of angiogenic signaling and considers the therapeutic potential of targeting these particular vascular factors.

引用

页数：11

共 132 条

[1] Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect [J].

Aase, K ;

von Euler, G ;

Li, X ;

Pontén, A ;

Thorén, P ;

Cao, R ;

Cao, Y ;

Olofsson, B ;

Gebre-Medhin, S ;

Pekny, M ;

Alitalo, K ;

Betsholtz, C ;

Eriksson, U .

CIRCULATION, 2001, 104 (03) :358-364

[2]

Adini A, 2002, CANCER RES, V62, P2749

[3]

[Anonymous], J CLIN ONCOL

[4]

[Anonymous], ASCO M

[5] Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 [J].

Autiero, M ;

Waltenberger, J ;

Communi, D ;

Kranz, A ;

Moons, L ;

Lambrechts, D ;

Kroll, J ;

Plaisance, S ;

De Mol, M ;

Bono, F ;

Kliche, S ;

Fellbrich, G ;

Ballmer-Hofer, K ;

Maglione, D ;

Mayr-Beyrle, U ;

Dewerchin, M ;

Dombrowski, S ;

Stanimirovic, D ;

Van Hummelen, P ;

Dehio, C ;

Hicklin, DJ ;

Persico, G ;

Herbert, JM ;

Communi, D ;

Shibuya, M ;

Collen, D ;

Conway, EM ;

Carmeliet, P .

NATURE MEDICINE, 2003, 9 (07) :936-943

[6] Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia [J].

Bellik, L ;

Vinci, MC ;

Filippi, S ;

Ledda, F ;

Parenti, A .

BRITISH JOURNAL OF PHARMACOLOGY, 2005, 146 (04) :568-575

[7] Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia [J].

Bellomo, D ;

Headrick, JP ;

Silins, GU ;

Paterson, CA ;

Thomas, PS ;

Gartside, M ;

Mould, A ;

Cahill, MM ;

Tonks, ID ;

Grimmond, SM ;

Townson, S ;

Wells, C ;

Little, M ;

Cummings, MC ;

Hayward, NK ;

Kay, GF .

CIRCULATION RESEARCH, 2000, 86 (02) :E29-E35

[8] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[9] Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor [J].

Birkenhager, R ;

Schneppe, B ;

Rockl, W ;

Wilting, J ;

Weich, HA ;

McCarthy, JEG .

BIOCHEMICAL JOURNAL, 1996, 316 :703-707

[10] Blockage of VEGF-induced angiogenesis by preventing VEGF secretion [J].

Björndahl, M ;

Cao, RH ;

Eriksson, A ;

Cao, YH .

CIRCULATION RESEARCH, 2004, 94 (11) :1443-1450

← 1 2 3 4 5 6 7 8 9 10 →